On a same-unit basis, total volume was up 1.3% versus the second quarter of 2019 with hospital-based services up by 10 basis points and office-based services up by 5.2%.
I'll add that other key metrics that were particularly volatile through last winter continued to show stable improving trends coming into the summer.
Payer mix remained favorable on a year-over-year basis for the second consecutive quarter and the rate of admission into our NICU did so as well.
As a result, our revenue for the quarter of $473 million was above our internal expectations, as was our adjusted EBITDA of $66 million.
But that said, our updated view for the full year includes our experience to date.
Looking forward beyond 2021 and count for the same risks, there are a number of factors that give me increased confidence that we'll see additional growth in adjusted EBITDA in 2022 that will get us pass the $270 million run rate we achieved pre-COVID.
I'll expand on these in three areas.
We want to make sure that patients that need our care receive our care as soon as possible.
